enGene Therapeutics, Inc. (ENGN)
1.56
-0.02
(-1.27%)
USD |
NASDAQ |
Oct 23, 16:00
1.565
0.00 (0.00%)
After-Hours: 20:00
enGene Therapeutics Enterprise Value : -128.59M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -128.59M |
| October 22, 2026 | -127.25M |
| October 21, 2026 | -123.90M |
| October 20, 2026 | -121.21M |
| October 19, 2026 | -127.25M |
| October 16, 2026 | -121.21M |
| October 15, 2026 | -118.53M |
| October 14, 2026 | -128.59M |
| October 13, 2026 | -123.90M |
| October 12, 2026 | -119.20M |
| October 09, 2026 | -117.19M |
| October 08, 2026 | -113.84M |
| October 07, 2026 | -116.19M |
| October 06, 2026 | -112.50M |
| October 05, 2026 | -107.81M |
| October 02, 2026 | -103.12M |
| October 01, 2026 | -100.44M |
| September 30, 2026 | -99.10M |
| September 29, 2026 | -102.45M |
| September 28, 2026 | -101.11M |
| September 25, 2026 | -101.78M |
| September 24, 2026 | -104.46M |
| September 23, 2026 | -99.10M |
| September 22, 2026 | -95.75M |
| September 21, 2026 | -101.78M |
| Date | Value |
|---|---|
| September 18, 2026 | -105.13M |
| September 17, 2026 | -105.13M |
| September 16, 2026 | -105.13M |
| September 15, 2026 | -106.47M |
| September 14, 2026 | -107.81M |
| September 11, 2026 | -112.50M |
| September 10, 2026 | -114.51M |
| September 09, 2026 | -109.15M |
| September 08, 2026 | -104.46M |
| September 04, 2026 | -111.16M |
| September 03, 2026 | -110.49M |
| September 02, 2026 | -106.47M |
| September 01, 2026 | -108.82M |
| August 31, 2026 | -109.82M |
| August 28, 2026 | -110.83M |
| August 27, 2026 | -105.13M |
| August 26, 2026 | -102.45M |
| August 25, 2026 | -107.81M |
| August 24, 2026 | -111.83M |
| August 21, 2026 | -113.84M |
| August 20, 2026 | -114.51M |
| August 19, 2026 | -109.15M |
| August 18, 2026 | -117.86M |
| August 17, 2026 | -119.20M |
| August 14, 2026 | -119.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals, Inc. | 1.862B |
| Medicus Pharma Ltd. | 155.00M |
| Xenon Pharmaceuticals, Inc. | 2.495B |
| Psyence Biomedical Ltd. | -- |
| Agenus, Inc. | 534.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.50M |
| Total Expenses (Quarterly) | 32.50M |
| EPS Diluted (Quarterly) | -0.4661 |
| Earnings Yield | -133.3% |
| Normalized Earnings Yield | -133.03 |